Alopecia Treatment Market is Expected To Witness a CAGR of 5.6% Over The Forecast Period 2018-2026 Estimated By Prominent Players Histogen, Inc., Aclaris Therapeutics, Inc., HCell Inc., GlaxoSmithKline Plc., Daiichi Sankyo, Inc., Cipla Limited

Alopecia also called as hair loss or baldness is very common condition affecting people across the globe. Alopecia can affect people of all gender and at any stage of life, it generally it affects mid-aged generation. For instance, according the data published by Arch Argent Pediatr in 2017, the prevalence of Alopecia areata is high in the age group of 10 and 25 years and around 60% of people under these age group suffer from Alopecia areata.

Get Sample Copy of Research Research @ https://bit.ly/2GVzA0i

Market Dynamics

Product launches, approvals, and robust pipeline of novel products is expected to be the major driver of growth of the global alopecia treatment market. For instance, in 2016, Cellmid Limited, a wholly owned subsidiary, Advangen Limited launched new hair loss product évolis in U.S. market. In May 2018, Histogen, Inc., received approval of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to study its lead product Hair Stimulating Complex (HSC660) in female diffuse hair loss. HSC660 is an investigational injectable treatment for alopecia and is expected to get FDA approval in near future. Key players in the market are engaged in strategic collaborations for increasing geographic presence in market. For instance, in May 2018, Cellmid Limited signed a collaborative agreement with Beijing Fukangren Bio-pharm Tech Co Ltd. for distribution of its product in Peoples Republic of China. Furthermore, the increasing prevalence of alopecia worldwide is expected to drive the growth of market. For instance, according to the data published by National Center for Biotechnology Information (NCBI), in 2015, androgenetic alopecia is most prevalent autoimmune disorder and the second most prevalent hair loss disorder and around 2% population worldwide is suffering from androgenetic alopecia.

Frequent launch, approvals, and robust pipeline of alopecia treatment products is expected to drive the growth of market

In recent past, regulatory bodies have approved novel drugs for treatment of alopecia and many drugs are in pipeline, which are expected to receive approval in near future. Approval of novel drugs and presence of robust drug pipeline is expected to drive global alopecia treatment market growth in near future. For instance, in January 2018, Concert Pharmaceuticals, Inc., a U.S.-based company received Fast Track designation from U.S. Food and Drug Administration (FDA) for its novel product CTP-543. CTP-543 is a novel, oral Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe alopecia areata. In April 2018, Concert Pharmaceuticals, Inc., finished patient recruitment for Phase 2a trial evaluating CTP-543 for the treatment of moderate-to-severe alopecia areata. In January 2018, HCell Inc., a Texas-based biotechnology company received Orphan Drug Designation (ODD) for HC017AA drug from U.S. Food and Drug Administration (FDA). HC017AA is an underdevelopment drug indicated for non- surgical treatment for Alopecia Areata in Pediatric Patients. In 2016, Galderma Laboratories, L.P., a company focused on development of dermatology and skin health launched its new qilib Hair Regrowth + Revitalization System and qilib Hair Health Reinforcement Biotin + Multivitamin Supplement. The qilib system is indicated for hair regrowth and contains clinically proven, prescription-strength minoxidil specifically formulated for men (5% minoxidil) or women (2% minoxidil). In 2017, Perrigo Company Plc. Launched over-the-counter (OTC) Women's Rogaine 5% minoxidil foam (minoxidil topical aerosol, 5% foam). Women's Rogaine 5% minoxidil foam (minoxidil topical aerosol, 5% foam) is indicated to regrow hair on top of the scalp. The launches of such novel products in market is expected to drive the global alopecia market growth in near future.

The global alopecia treatment market size was valued at US$ 7.4 Bn in 2017, and is expected to witness a CAGR of 5.6% over the forecast period (2018 – 2026).

Key Players - Alopecia Treatment Market

Key players operating in the alopecia treatment market include

1. Histogen, Inc.
2. Aclaris Therapeutics, Inc.
3. Concert Pharmaceuticals, Inc.
4. HCell Inc.
5. GlaxoSmithKline Plc.
6. Daiichi Sankyo, Inc.
7. Cipla Limited, and others

Detailed Segmentation:

By Disease Type: Androgenic Alopecia, Alopecia Areata, Ciatricial Alopecia, Traction Alopecia, Alopecia Totalis

By Drug Type:
Vasodilators - Minoxidil
5-Alpha Reductase Inhibitors - Finasteride
Corticosteroids
Immunosuppressants - Cyclosporine, Others
Others

By Gender: Male, Female
By Route of Administration: Oral, Topical, Injectable
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Geography: North America, Europe, Asia Pacific, Latin America, Middle East, Africa

Else Place an Enquiry Before Purchase @ https://bit.ly/2Ekz4Fw

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at sales@coherentmarketinsights.com

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.